arXiv subjects

Eunhee Kim

Publications and source records attributed to Eunhee Kim.

3 recordsLinked to original sources

arXiv2025

Controllable Long-term Motion Generation with Extended Joint Targets

Generating stable and controllable character motion in real-time is a key challenge in computer animation. Existing methods often fail to provide fine-grained control or suffer from motion degradation over long sequences, limiting their use in interactive applications. We propose COMET, an autoregressive framework that runs in real time, enabling versatile character control and robust long-horizon synthesis. Our efficient Transformer-based conditional VAE allows for precise, interactive control over arbitrary user-specified joints for tasks like goal-reaching and in-betweening from a single model. To ensure long-term temporal stability, we introduce a novel reference-guided feedback mechanism that prevents error accumulation. This mechanism also serves as a plug-and-play stylization module, enabling real-time style transfer. Extensive evaluations demonstrate that COMET robustly generates high-quality motion at real-time speeds, significantly outperforming state-of-the-art approaches in complex motion control tasks and confirming its readiness for demanding interactive applications.

cs.CV↗

arXiv2025

TITE-STEIN: Time-to-event Simple Toxicity and Efficacy Interval Design to Accelerate Phase I/II Trials

Oncology dose-finding trials are shifting from identifying the maximum tolerated dose (MTD) to determining the optimal biological dose (OBD), driven by the need for efficient methods that consider both toxicity and efficacy. This is particularly important for novel therapies, such as immunotherapies and molecularly targeted therapies, which often exhibit non-monotonic dose-efficacy curves. However, making timely adaptive dosing decisions is challenging due to the rapid patient accrual rate and the late-onset toxicity and/or efficacy outcomes associated with these therapies. The Simple Toxicity and Efficacy Interval (STEIN) design has demonstrated strong performance in accommodating diverse dose-efficacy patterns and incorporating both toxicity and efficacy outcomes to select the OBD. However, the rapid accrual of patients and the often-delayed onset of toxicity and/or efficacy pose challenges to timely adaptive dose decisions. To address these challenges, we propose TITE-STEIN, a model-assisted design that incorporates time-to-event (TITE) outcomes for toxicity and/or efficacy, by extending STEIN. In this article, we demonstrate that TITE-STEIN significantly shortens trial duration compared to STEIN. Furthermore, by integrating an OBD verification procedure during OBD selection, TITE-STEIN effectively mitigates the risk of exposing patients to inadmissible doses when the OBD does not exist. Extensive simulations demonstrate that TITE-STEIN outperforms existing TITE designs, including TITE-BONI12, TITE-BOIN-ET, LO-TC, and Joint TITE-CRM, by selecting the OBD more accurately, allocating more patients to it, and improving overdose control.

stat.ME↗

arXiv2024

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology

Traditional phase I dose finding cancer clinical trial designs aim to determine the maximum tolerated dose (MTD) of the investigational cytotoxic agent based on a single toxicity outcome, assuming a monotone dose-response relationship. However, this assumption might not always hold for newly emerging therapies such as immuno-oncology therapies and molecularly targeted therapies, making conventional dose finding trial designs based on toxicity no longer appropriate. To tackle this issue, numerous early phase dose finding clinical trial designs have been developed to identify the optimal biological dose (OBD), which takes both toxicity and efficacy outcomes into account. In this article, we review the current model-assisted dose finding designs, BOIN-ET, BOIN12, UBI, TEPI-2, PRINTE, STEIN, and uTPI to identify the OBD and compare their operating characteristics. Extensive simulation studies and a case study using a CAR T-cell therapy phase I trial have been conducted to compare the performance of the aforementioned designs under different possible dose-response relationship scenarios. The simulation results demonstrate that the performance of different designs varies depending on the particular dose-response relationship and the specific metric considered. Based on our simulation results and practical considerations, STEIN, PRINTE, and BOIN12 outperform the other designs from different perspectives.

stat.ME↗